Tirzepatide for the treatment of adults with type 2 diabetes

Tirzepatide (Mounjaro) is a dual GLP‐1/GIP receptor agonist for the treatment of type 2 diabetes in adults. This article discusses its administration, clinical trial efficacy and adverse effects.

[1]  R. Gabbay,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). , 2022, Diabetes care.

[2]  P. Norwood,et al.  Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. , 2022, JAMA.

[3]  B. Ludvik,et al.  Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial , 2021, The Lancet.

[4]  J. Rosenstock,et al.  Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial , 2021, The Lancet.

[5]  J. Rosenstock,et al.  Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. , 2021, The New England journal of medicine.

[6]  A. Davies,et al.  Recommendations on the Use of Open Surgical and Endovascular Aneurysm Repair for the Management of Unruptured Abdominal Aortic Aneurysm from the Guideline Development Committee Appointed by the UK National Institute for Health and Care Excellence. , 2021, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[7]  A. Hess,et al.  Management. , 2020, Anesthesiology.

[8]  Codipar 15MG500MG,et al.  Public Assessment Report , 2006 .